EnsoData announces the acquisition of sleep testing diagnostic technology from Resonea aimed at reducing the cost of systematically addressing sleep apnea across large patient populations. With this acquisition, EnsoData adds acoustic flow and microphone data channels to enable an exciting new way to pre-screen patients for sleep apnea with an FDA-cleared mobile application and extend the diagnostic capabilities of home sleep testing. Currently, the most common paths for sleep apnea screening involve face-to-face patient-to-physician conversations and rely on the use of sleep health scree ..read more

sovaSage, a privately held company specializing in AI-based software and services for the management of obstructive sleep apnea, today announced the promotion of Mr. Jamie Caputo to Vice President of Sales. In 2020, sovaSage introduced the first AI-based software platform designed to select and fit the optimal PAP mask for OSA patients. In early 2023, the Company introduced its next innovative product, TherapistAssist JeanieTM. Jeanie is the world’s first Virtual Sleep Coach, available, 24/7/365, a PAP compliance management platform, augmented with the industry’s leading live support sleep coa ..read more

The role of sleep in optimizing health and well-being is a widely discussed topic in popular culture and research communities. However, one area where discussion is lacking is the interplay between sleep and dermatology. In this article, we discuss the complex interplay between sleep and skin health, as well as review how poor sleep may contribute to worsening of skin disease in patients living with chronic dermatologic conditions like psoriasis and eczema. Don’t Sleep on the Skin The skin is the body’s largest and primary protective organ, serving as a first-order physical barrier against the ..read more

React Health and ReactDx, leading companies in respiratory, sleep, and cardiac care, have announced the adoption of new, joint mission and vision statements that underscore their commitment to optimizing individuals’ well-being through pioneering advanced diagnostics and therapeutics. The new mission, “To improve the lives of those we serve by delivering an innovative continuum of diagnostics and medical devices, with excellent respiratory, sleep and cardiac care.” In addition to the new mission statement, React Health and ReactDx have articulated a bold new vision: “To seamlessly integrate e ..read more

Panthera Dental  is pleased to announce a remarkable milestone in its ongoing commitment to innovation and excellence: the company now holds over 110 patents across the dental, medical, and sleep appliance industries. This significant milestone follows their recent amicable settlement with ResMed SAS that resolves all ongoing patent infringement litigation between Panthera and ResMed SAS in relation to Panthera’s mandibular repositioning devices. Intellectual property is a critical component of the innovation that drives Panthera’s strategic development. As such, this settlement was an im ..read more

Masimo has announced a groundbreaking update to its advanced health-tracking wearable, the Masimo W1® Sport. The new feature, Sleep Halo, offers scientifically based sleep analysis, setting a new standard in sleep tracking technology. Unmatched Sleep Data Tracking and Comprehensive Sleep Insights Sleep Halo delivers unparalleled overnight sleep data tracking, recording over 70,000 daily measurements of second-by-second continuous health data. This feature leverages continuous Masimo pulse oximetry and machine learning to provide in-depth insights into sleep quality. The insights include overal ..read more

Harmony Biosciences announced that the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for WAKIX® (pitolisant) tablets for the treatment of excessive daytime sleepiness (EDS) in pediatric patients six years of age and older with narcolepsy. The FDA separated the submission into two sNDAs for administrative purposes to issue an approval for the treatment of EDS and a complete response for the treatment of cataplexy in pediatric patients (6 to <18 years of age) with narcolepsy. The FDA granted priority review of the sNDA based on a Phase 3 stu ..read more

Clinicians today have numerous options for prescribing home sleep apnea testing (HSAT). While sleep laboratory type 1 tests based on polysomnography (PSG) utilize an array of sensors, belts, technologies, and experts to monitor the patient, at-home tests generally gather less information in favor of convenience, comfort, and accessibility. Two respiratory inductance plethysmography (RIP) belts measuring respiratory movement—positioned around the torso beneath the armpits and at the umbilicus—are the “gold standard” in the lab setting, according to Paul Raymond, MD. However, two belts aren’t al ..read more

Incannex Healthcare Inc., a pharmaceutical company developing unique medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, is pleased to announce that patient dosing has commenced in the Company’s Phase 2/3 clinical trial to assess the safety and efficacy of IHL-42X in patients with obstructive sleep apnea (OSA). IHL-42X is the Company’s proprietary fixed-dose combination drug for the treatment of obstructive sleep apnea. Commencement of patient dosing in the United States represents a significant milestone in its development. Initiating dosing in the trial follows the op ..read more

IntelliPAP is a new optional tool for physicians to use in noninvasive ventilation for patients with respiratory insufficiency and obstructive sleep apnea (OSA). This innovative device automatically adjusts the positive end-expiratory pressure (PEEP) levels in response to sleep-disordered breathing (SDB) events. To enhance safety, clinicians can set minimum and maximum PEEP levels. Key Takeaways: IntelliPAP Benefits: Facilitates automatic adjustment of PEEP levels, improving treatment for respiratory insufficiency and OSA. Safety Features: Clinicians can customize the range of PEEP adjustment ..read more